临床局限性前列腺癌:AUA/ASTRO指南2026年修正版
修正版更新了影像学、共享决策(SDM)、放射治疗及疾病管理等方面的推荐意见。
要点
- 基于29项全文审查研究及8项AI相关研究更新证据。
- 修正内容涉及影像学、共享决策(SDM)、放射治疗及疾病管理。
- 指南需随诊断与治疗选项演变持续审查。
核心结论
- 2026年AUA/ASTRO指南修正版为临床局限性前列腺癌的评估与管理提供更新后的临床框架。
主要发现
- 修正版在影像学、共享决策(SDM)、放射治疗及疾病管理方面提供新的或修订的指导。
临床怎么用
- 临床医生可参照修正版推荐更新临床局限性前列腺癌的影像学评估、共享决策及放射治疗决策。
局限性
- 指南需随诊断与治疗选项的持续演变进一步审查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2022 publication of this Guideline via the AUA Amendment process. The resulting 2026 Guideline Amendment addresses updated recommendations to provide a clinical framework for the evaluation and management of clinically localized prostate cancer. MATERIALS AND METHODS: In 2025, this Guideline was reviewed via the AUA ULR process, which identified 29 studies for full-text review that were published between July 1, 2021 and December 5, 2024. An additional 8 studies were identified reviewing artificial intelligence (AI) as it relates to disease management. Relevant studies were incorporated into the Guideline evidence base, and Guideline statements were updated as appropriate. RESULTS: The Panel developed evidence- and consensus-based statements based on an updated review to provide guidance on evaluation and management of clinically localized prostate cancer. These updates are detailed herein. CONCLUSIONS: This Amendment provides several new insights, including revised guidance on imaging, updated information on shared decision-making (SDM), and new direction regarding radiation treatment and disease management. This Guideline will require further review as the diagnostic and treatment options in this space continue to evolve.
引用
- Eastham JA, Barocas DA, Chu CE, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026). J Urol. 2026. PMID: 41988960. doi:10.1097/JU.0000000000005060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。